Entera Bio Ltd. EBT

EBT of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBT growth rates and interactive chart. Earnings before tax (EBT) measures a company's financial performance. Its calculation is revenue minus expenses, excluding taxes. EBT is a line item on a company's income statement. It shows company earnings with the cost of goods sold (COGS), interest, depreciation, general and administrative expenses, and other operating expenses deducted from gross sales.


Highlights and Quick Summary

  • EBT for the quarter ending June 29, 2020 was $-3.19 Million (a 9.32% increase compared to previous quarter)
  • Year-over-year quarterly EBT increased by 6.55%
  • Annual EBT for 2019 was $-10.8 Million (a 4.77% increase from previous year)
  • Annual EBT for 2018 was $-10.3 Million (a -7.98% decrease from previous year)
  • Twelve month EBT ending June 29, 2020 was $-12.5 Million (a 17.02% increase compared to previous quarter)
  • Twelve month trailing EBT increased by 25.42% year-over-year
Trailing EBT for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$-12.5 Million $-10.7 Million $-10.8 Million $-10 Million
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBT of Entera Bio Ltd.

Most recent EBTof ENTX including historical data for past 10 years.

Interactive Chart of EBT of Entera Bio Ltd.

Entera Bio Ltd. EBT for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-3.19 $-2.92
2019 $-3.44 $-2.99 $-1.37 $-3.0 $-10.8
2018 $-2.65 $-5.07 $1.56 $-4.16 $-10.3
2017 $-11.2

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.